Komori
Presentation materials for financial results2934J Frontier Co.,Ltd.Food

Financial Results Presentation for the First Quarter of the Fiscal Year Ending May 2027

In the first quarter of the fiscal year ending May 2027, operating profit was ¥83 million, despite the quarter generally being prone to losses, representing 8.0% progress against the full-year operating profit forecast. Sales increased 18.0% year on year, while EBITDA increased 89.7%.

Worth reading
58In focus
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
83
¥ million
Wording
Definitive
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFirst quarter of the fiscal year ending May 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥5,899 million+18.0%
Operating profit¥83 million
Ordinary income¥68 million
Net income¥-10 million
Operating profit margin
rate_pct1.4
yoy_change_points1.7
Results for the three months of the current quarter
Net Sales
¥5,899 million
EBITDA
¥236 million
Operating profit
¥83 million
Ordinary income
¥68 million
Profit attributable to owners of the parent
¥-10 million
Full-year earnings forecast
Net Sales
¥26,500 million
EBITDA
¥1,700 million
Operating profit
¥1,050 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales22.3%
EBITDA13.9%
Operating profit8.0%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Significantly exceeded plan
New initiatives
  • Revision of the SOKUYAKU fee structure for clinics and pharmacies
  • Basic agreement and service integration toward a comprehensive business alliance with Rakuten Group
  • Business alliance with エアロネクスト concerning drone delivery of pharmaceuticals
  • Business alliance with アプリックスグループ concerning online medical consultations
  • Addition of next-appointment registration and medical-record ID management functions to SOKUYAKU
  • Planned introduction of Rakuten Pay (online payments)
  • Launch of general Amazon sales for the new men’s cosmetics brand ROCT
Key KPIsA metric the company considers important as a management benchmark.
  • QAU (quarterly active users)114 10,000 people
  • ARR (annual recurring revenue)103 Hundreds of millions of yen
  • Number of SOKUYAKU Benefit registrantsOver 200% year on year
    Year on year against the same period last yearOver 200% year on year
  • Number of partner clinics4,000 clinics
  • Number of partner pharmacies20,000 Location
  • Cumulative units sold of 『北国の恵み』500 10,000 bags
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • New orders in the SOKUYAKU businessSteady
  • Cancellations after the fee revisionNone
  • Active patient usersIncreased
  • Volume and unit priceGrowth exceeded expectations on both fronts
Segment results
  • Medical Care Sales business
    Net Sales¥1,507 million
    Revenue_yoy_pct17.9
    EBITDA¥152 million
    EBITDA_yoy_pct95.9
  • Healthcare Sales business
    Net Sales¥1,293 million
    Revenue_yoy_pct-8.4
    EBITDA¥-12 million
  • Healthcare Marketing business
    Net Sales¥3,098 million
    Revenue_yoy_pct34.1
    EBITDA¥190 million
    EBITDA_yoy_pct863.9
Medium-term management plan targets
Deepening the SOKUYAKU healthcare ecosystem in Japan and creating the same ecosystem in Asian markets
Market Size / Share
  • Global Telemedicine Market
    Value
    2020 15.2 / 2028 60.1
  • Japan's online medical consultation marketExpected to expand from 2022 to 2028
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFirst quarter of the fiscal year ending May 2027
Net Sales¥5,899 million (YoY +18.0%)
Operating profit¥83 million
Ordinary income¥68 million
Net income¥-10 million
Operating profit marginrate_pct 1.4 / yoy_change_points 1.7
Results for the three months of the current quarterNet Sales ¥5,899 million / EBITDA ¥236 million / Operating profit ¥83 million / Ordinary income ¥68 million / Profit attributable to owners of the parent ¥-10 million
Full-year earnings forecastNet Sales ¥26,500 million / EBITDA ¥1,700 million / Operating profit ¥1,050 million
Progress against full-year forecastNet Sales 22.3% / EBITDA 13.9% / Operating profit 8.0%
Self-assessment against the planSignificantly exceeded plan
Segment resultsSegment Medical Care Sales business / Net Sales ¥1,507 million / Revenue_yoy_pct 17.9 / EBITDA ¥152 million / EBITDA_yoy_pct 95.9, Segment Healthcare Sales business / Net Sales ¥1,293 million / Revenue_yoy_pct -8.4 / EBITDA ¥-12 million / EBITDA_yoy_pct Not disclosed, Segment Healthcare Marketing business / Net Sales ¥3,098 million / Revenue_yoy_pct 34.1 / EBITDA ¥190 million / EBITDA_yoy_pct 863.9
Key KPIsIndicator name QAU (quarterly active users) / Value 114 10,000 people / Year on year against the same period last year Not disclosed, Indicator name ARR (annual recurring revenue) / Value 103 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name Number of SOKUYAKU Benefit registrants / Value Over 200% year on year / Year on year against the same period last year Over 200% year on year, Indicator name Number of partner clinics / Value 4,000 clinics / Year on year against the same period last year Not disclosed, Indicator name Number of partner pharmacies / Value 20,000 Location / Year on year against the same period last year Not disclosed, Indicator name Cumulative units sold of 『北国の恵み』 / Value 500 10,000 bags / Year on year against the same period last year Not disclosed
Unit price and quantity metricsIndicator name New orders in the SOKUYAKU business / Value Steady / Year on year against the same period last year Not disclosed, Indicator name Cancellations after the fee revision / Value None / Year on year against the same period last year Not disclosed, Indicator name Active patient users / Value Increased / Year on year against the same period last year Not disclosed, Indicator name Volume and unit price / Value Growth exceeded expectations on both fronts / Year on year against the same period last year Not disclosed
Medium-term management plan targetsDeepening the SOKUYAKU healthcare ecosystem in Japan and creating the same ecosystem in Asian markets
Market Size / ShareMarket Global Telemedicine Market / Value 2020 15.2 / 2028 60.1, Market Japan's online medical consultation market / Value Expected to expand from 2022 to 2028
New initiativesRevision of the SOKUYAKU fee structure for clinics and pharmacies, Basic agreement and service integration toward a comprehensive business alliance with Rakuten Group, Business alliance with エアロネクスト concerning drone delivery of pharmaceuticals, Business alliance with アプリックスグループ concerning online medical consultations, Addition of next-appointment registration and medical-record ID management functions to SOKUYAKU, Planned introduction of Rakuten Pay (online payments), Launch of general Amazon sales for the new men’s cosmetics brand ROCT
Items this document does not state (14)
Gross Profit MarginSelling, general and administrative expensesBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Profitability in the SOKUYAKU business improved following revisions to the fee structure for clinics and pharmacies and growth in the number of SOKUYAKU Benefit registrants, while sales of the Shokansen series performed well in the pharmaceutical D2C business. In the healthcare marketing business, marketing support for D2C operators and highly profitable logistics projects contributed to results. In the healthcare sales business, however, EBITDA declined as advertising investment was increased to acquire new subscription customers whose sales contributions are expected from the second quarter onward.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation for the First Quarter of the Fiscal Year Ending May 2027 | J Frontier Co.,Ltd. (2934) timely disclosure | Komori